Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono to invest €150m in China R&D

Merck Serono has announced plans to invest more than €150m and create over 200 jobs through establishing a global R&D centre in Beijing, China

Merck Serono has revealed plans to invest more than €150m and create over 200 qualified jobs over the next four years through establishing a global research and development centre in Beijing, China. Merck Serono China currently has over 1,000 employees nationwide.

The company expects the China R&D organisation to sit alongside its hubs in Germany, Switzerland and the US as key worldwide R&D hubs for Merck Serono.

"The creation of the China R&D centre marks a new milestone in Merck Serono's commitment to China, where there is a rising demand for more healthcare options," said Elmar Schnee, president of Merck Serono.

Drug development for China and other Asian countries, including local clinical trials and participation in global trials, will be led by the China team. The team will seek out partnerships with local companies and academic institutions, and ensure collaborations with research institutions in China are managed effectively.

Pharmacogenomics, bioanalytics and other biomarker research will be the key focus of the Beijing R&D centre.

The Swiss-based company's key products  Erbitux (cancer), Rebif (multiple sclerosis), Gobal-f (infertility), Saizen (endocrine and metabolic disorders) and Concor and Euthyrox (cardiometabolic diseases) are already available in the country through Merck Serono China.

23rd November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics